Beinaglutide
GLP-1 · s.c. daily · Benemae
Summary
- Also known as
- Benemae
- Mechanism
- GLP-1
- Route
- s.c. daily
- Company
- Benemae
- Highest development stage
- approved
- Status (as of data cut)
- Approved in China: T2D (2016), weight management (2023) verify
- Next milestone
- —
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 4 approved / in label | NMPA (China), weight management, July 2023 | ChemLinked |
| T2D | 4 approved / in label | NMPA (China), 2016 | Frontiers in Pharmacology 2024 |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 3 weight management (ChiCTR1900023428) | 0.2 mg TID | obesity china | 16 | 282 | — | —−6.0 % vs −2.4 % estimand not specified | — | 5.9 vs 0.7 | — | 49.3 vs 7.1 | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (3)
- 0.2 mg TID · weight_unsp · publication
Mean body weight change from baseline to week 16 was -6.0% and -2.4% in the beinaglutide (n = 282) and placebo (n = 138) groups
- 0.2 mg TID · nausea · publication
Nausea (transient and mild-to-moderate) was the most common adverse event in the beinaglutide group (49.3% vs. 7.1% [placebo]).
- 0.2 mg TID · ae_dc · publication
More patients receiving beinaglutide discontinued treatment because of adverse events (5.9% vs. 0.7% [placebo]).
Registered trials (1)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT03986008 Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients | Obesity | Phase 3 | unknown | 2019-12 → 2021-12 | 60 | unknown | NCT03986008 |
Primary sources
How to cite this page
Cite the primary publication for any single result; every value above links to it.